Neurology & Neuroscience

7+ min ago   (126+ words) This product is not necessarily endorsed by the Fisher Center Foundation, or our scientists; the article is intended for informational purposes only. Please consult your doctor to see if this, or any other drug, is right for you. On July…...

3+ hour, 14+ min ago   (140+ words) However, the loss of exclusivity of several key branded products will be a challenge. The Parkinson’s disease (PD) market across the seven major markets is set to grow to $7.2b in 2033, driven by launches of disease-modifying therapies and approved symptomatic treatments…...

2+ hour, 1+ min ago   (558+ words) Difficulty falling asleep, waking up repeatedly or feeling tired despite spending enough time in bed can affect both physical and mental health. Understanding insomnia is the first step towards better sleep. Insomnia is a sleep disorder characterised by difficulty falling…...

5+ hour, 54+ min ago   (186+ words) Holy Cross Health achieved high performance in stroke, heart failure and diabetes from AHA’s Get With The Guidelines® program. Submitted by Paige Feigenbaum and Joseph Guastaferro Holy Cross Health is one of seven hospitals in the entire state of Florida…...

16+ hour, 41+ min ago   (1163+ words) If you have unusual urges to urinate, your healthcare professional checks for an infection or blood in your urine. Your health professional also may check to see if you're emptying your bladder all the way when you urinate. Your appointment…...

6+ hour, 10+ min ago   (468+ words) About a third of adults in the U.S. don’t get the recommended seven hours of sleep a night. That shortened sleep has been associated with a host of chronic health conditions like Type 2 diabetes, hypertension, coronary heart disease and stroke. But…...

1+ hour, 7+ min ago   (276+ words) SGLT2 inhibitors have moved from a diabetes-specific therapy to a guideline-endorsed foundation of cardio-kidney-metabolic care, with generic availability now accelerating access among clinicians and patients who previously faced real barriers to these therapies. Welcome back to another AJMC Insights series In…...

1+ hour, 7+ min ago   (276+ words) Switching stable patients between SGLT2 inhibitors, including to generics, is generally well tolerated, but any gap in therapy during the transition carries real cardio-kidney risk that clinicians should work to avoid. In "Switching SGLT2 Inhibitors: Generic Transitions and Continuity of Care," Dr…...

1+ hour, 7+ min ago   (271+ words) Payers weighing SGLT2 inhibitors as a class must account for a mortality signal that appears strongest in the highest-risk patients, without letting that population-dependent nuance restrict broader, evidence-supported access to the class. "SGLT2 Inhibitors as a Class Effect: Payer and Formulary Considerations…...

1+ hour, 8+ min ago   (187+ words) The American Journal of Managed Care Welcome back to another AJMC Insights series In "SGLT2 Inhibitors' Cardiorenal Expansion Reshapes Formulary Strategy," Ryan Haumschild, PharmD, MS, MBA, CPEL opens the series by reframing SGLT2 inhibitors as foundational cardiorenal therapy rather than diabetes-only agents…...